136 related articles for article (PubMed ID: 38010032)
1. Kristen rat sarcoma virus (KRAS) G12F-positive non-small cell lung cancer mimicking KRAS G12C positivity: A case report.
Oi I; Ito T; Saito Z; Imakita T; Kanai O; Fujita K; Tachibana H; Mio T
Thorac Cancer; 2024 Jan; 15(3):271-273. PubMed ID: 38010032
[TBL] [Abstract][Full Text] [Related]
2. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
3. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
[TBL] [Abstract][Full Text] [Related]
4. Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.
Boby JM; Mohd Ghazali NN; Mani A; George M
J Med Case Rep; 2022 Nov; 16(1):420. PubMed ID: 36329437
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
Hoshiyama H
Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
[TBL] [Abstract][Full Text] [Related]
6. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib: a case report.
Jiang Y; Liu X; Lv DL; Zhao XL
Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588
[TBL] [Abstract][Full Text] [Related]
7. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
9. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
10. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
[TBL] [Abstract][Full Text] [Related]
11. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
12. KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.
Frost MG; Jensen KJ; Gotfredsen DR; Sørensen AMS; Ankarfeldt MZ; Louie KS; Sroczynski N; Jakobsen E; Andersen JL; Jimenez-Solem E; Petersen TS
Lung Cancer; 2023 Apr; 178():172-182. PubMed ID: 36868178
[TBL] [Abstract][Full Text] [Related]
13. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
14. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
Mazzaschi G; Perrone F; Minari R; Verzè M; Azzoni C; Bottarelli L; Pluchino M; Armillotta MP; Ubaldi A; Altimari A; Gruppioni E; Sperandi F; Andrini E; Guaitoli G; Bettelli S; Longo L; Bertolini F; Barbieri F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Gnetti L; Tiseo M;
Clin Lung Cancer; 2022 Nov; 23(7):e478-e488. PubMed ID: 36002369
[TBL] [Abstract][Full Text] [Related]
16. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ
Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782
[TBL] [Abstract][Full Text] [Related]
17. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry.
Isaksson J; Berglund A; Louie K; Willén L; Hamidian A; Edsjö A; Enlund F; Planck M; Vikström A; Johansson M; Hallqvist A; Wagenius G; Botling J
Clin Lung Cancer; 2023 Sep; 24(6):507-518. PubMed ID: 37296038
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
Bauml JM; Li BT; Velcheti V; Govindan R; Curioni-Fontecedro A; Dooms C; Takahashi T; Duda AW; Odegaard JI; Cruz-Guilloty F; Jin L; Zhang Y; Anderson A; Skoulidis F
Lung Cancer; 2022 Apr; 166():270-278. PubMed ID: 34838325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
